Cargando…
Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management
BACKGROUND: Histidine-tryptophan-ketoglutarate (HTK) is a solution commonly used for organ transplantation. However, there is no certified fixed regimen for on-pump heart surgery in neonates. We aimed to retrospectively evaluate the outcomes related to different HTK dosages and to analyze the safety...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710314/ https://www.ncbi.nlm.nih.gov/pubmed/34711715 http://dx.doi.org/10.1097/CM9.0000000000001643 |
_version_ | 1784623124403191808 |
---|---|
author | Bai, Li-Ting Tong, Yuan-Yuan Liu, Jin-Ping Feng, Zheng-Yi Zhao, Ju Guo, Sheng-Wen Jin, Yu Zhang, Pei-Yao Li, Yi-Xuan |
author_facet | Bai, Li-Ting Tong, Yuan-Yuan Liu, Jin-Ping Feng, Zheng-Yi Zhao, Ju Guo, Sheng-Wen Jin, Yu Zhang, Pei-Yao Li, Yi-Xuan |
author_sort | Bai, Li-Ting |
collection | PubMed |
description | BACKGROUND: Histidine-tryptophan-ketoglutarate (HTK) is a solution commonly used for organ transplantation. However, there is no certified fixed regimen for on-pump heart surgery in neonates. We aimed to retrospectively evaluate the outcomes related to different HTK dosages and to analyze the safety of high-dosage perfusion. METHODS: A total of 146 neonates who underwent on-pump heart surgery with single-shot HTK perfusion were divided into two groups according to HTK dosages: a standard-dose (SD) group (n = 63, 40 mL/kg < HTK ≤ 60 mL/kg) and a high-dose (HD) group (n = 83, HTK >60 mL/kg). Propensity score matching (PSM) was performed to control confounding bias. RESULTS: The SD group had a higher weight (3.7 ± 0.4 vs. 3.4 ± 0.4 kg, P < 0.0001), a lower proportion of complete transposition of the great artery (69.8% vs. 85.5%, P = 0.022), a lower cardiopulmonary bypass (CPB) time (123.5 [108.0, 136.0] vs. 132.5 [114.8, 152.5] min, P = 0.034), and a lower aortic x-clamp time (82.9 ± 27.1 vs. 95.5 ± 26.0 min, P = 0.005). After PSM, 44 patients were assigned to each group; baseline characteristics and CPB parameters between the two groups were comparable. There were no significant differences in peri-CPB blood product consumption after PSM (P > 0.05). The incidences of post-operative complications were not significantly different between the two groups. There were no significant differences in ventilation time, intensive care unit stay, and post-operative hospital stay (P > 0.05). Follow-up echocardiography outcomes at 1 month, 3 to 6 months, and 1 year showed that left ventricular ejection fraction and end-diastolic dimension were comparable between the two groups. CONCLUSIONS: In neonatal on-pump cardiac surgery patients, single-shot HD (>60 mL/kg) HTK perfusion had a comparable heart protection effect and short-term post-operative prognosis as standard dosage perfusion of 40 to 60 mL/kg. Thus, this study provides supporting evidence of the safety of HD HTK perfusion. |
format | Online Article Text |
id | pubmed-8710314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-87103142021-12-28 Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management Bai, Li-Ting Tong, Yuan-Yuan Liu, Jin-Ping Feng, Zheng-Yi Zhao, Ju Guo, Sheng-Wen Jin, Yu Zhang, Pei-Yao Li, Yi-Xuan Chin Med J (Engl) Original Articles BACKGROUND: Histidine-tryptophan-ketoglutarate (HTK) is a solution commonly used for organ transplantation. However, there is no certified fixed regimen for on-pump heart surgery in neonates. We aimed to retrospectively evaluate the outcomes related to different HTK dosages and to analyze the safety of high-dosage perfusion. METHODS: A total of 146 neonates who underwent on-pump heart surgery with single-shot HTK perfusion were divided into two groups according to HTK dosages: a standard-dose (SD) group (n = 63, 40 mL/kg < HTK ≤ 60 mL/kg) and a high-dose (HD) group (n = 83, HTK >60 mL/kg). Propensity score matching (PSM) was performed to control confounding bias. RESULTS: The SD group had a higher weight (3.7 ± 0.4 vs. 3.4 ± 0.4 kg, P < 0.0001), a lower proportion of complete transposition of the great artery (69.8% vs. 85.5%, P = 0.022), a lower cardiopulmonary bypass (CPB) time (123.5 [108.0, 136.0] vs. 132.5 [114.8, 152.5] min, P = 0.034), and a lower aortic x-clamp time (82.9 ± 27.1 vs. 95.5 ± 26.0 min, P = 0.005). After PSM, 44 patients were assigned to each group; baseline characteristics and CPB parameters between the two groups were comparable. There were no significant differences in peri-CPB blood product consumption after PSM (P > 0.05). The incidences of post-operative complications were not significantly different between the two groups. There were no significant differences in ventilation time, intensive care unit stay, and post-operative hospital stay (P > 0.05). Follow-up echocardiography outcomes at 1 month, 3 to 6 months, and 1 year showed that left ventricular ejection fraction and end-diastolic dimension were comparable between the two groups. CONCLUSIONS: In neonatal on-pump cardiac surgery patients, single-shot HD (>60 mL/kg) HTK perfusion had a comparable heart protection effect and short-term post-operative prognosis as standard dosage perfusion of 40 to 60 mL/kg. Thus, this study provides supporting evidence of the safety of HD HTK perfusion. Lippincott Williams & Wilkins 2021-12-20 2021-10-26 /pmc/articles/PMC8710314/ /pubmed/34711715 http://dx.doi.org/10.1097/CM9.0000000000001643 Text en Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Original Articles Bai, Li-Ting Tong, Yuan-Yuan Liu, Jin-Ping Feng, Zheng-Yi Zhao, Ju Guo, Sheng-Wen Jin, Yu Zhang, Pei-Yao Li, Yi-Xuan Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management |
title | Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management |
title_full | Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management |
title_fullStr | Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management |
title_full_unstemmed | Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management |
title_short | Comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management |
title_sort | comparable prognosis in different neonatal histidine-tryptophan-ketoglutarate dosage management |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710314/ https://www.ncbi.nlm.nih.gov/pubmed/34711715 http://dx.doi.org/10.1097/CM9.0000000000001643 |
work_keys_str_mv | AT bailiting comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement AT tongyuanyuan comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement AT liujinping comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement AT fengzhengyi comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement AT zhaoju comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement AT guoshengwen comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement AT jinyu comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement AT zhangpeiyao comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement AT liyixuan comparableprognosisindifferentneonatalhistidinetryptophanketoglutaratedosagemanagement |